Cipla Challenges HIV Drug Tender | Johannesburg News
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Cipla Challenges HIV Drug Tender | Johannesburg News
-
ナレーター：
-
著者：
A massive 15.5 billion rand AIDS drug tender is at the center of a high-stakes legal battle, as pharmaceutical giant Cipla challenges the South African health department’s contract awards. Despite past partnerships and local manufacturing investments, Cipla was excluded from key HIV treatment contracts set to begin December 2025, sparking claims of unfairness and collusion. The government counters that the bidding process was rational and transparent, highlighting that Cipla’s prices were higher than winners and that they failed to meet negotiated price targets — potentially costing the state an extra 75 million rand. Cipla’s allegations against rivals Barrs and Innovata are dismissed by officials, who note no evidence of collusion or improper affiliations. With court hearings scheduled for September, this case could reshape how public health tenders are awarded — and who gets to supply life-saving medication.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/75fa31f4bf2959ed